Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/227955
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Cardiomyocytes Derived from Induced Pluripotent Stem Cells as a Disease Model for Propionic Acidemia

AutorAlonso-Barroso, Esmeralda; Pérez, Belén CSIC ORCID; Ruiz Desviat, Lourdes; Richard, Eva CSIC ORCID
Palabras clavePropionic acidemia
Cardiac dysfunction
iPSC
iPSC-derived cardiomyocytes
Disease model
Fecha de publicación25-ene-2021
EditorMultidisciplinary Digital Publishing Institute
CitaciónInternational Journal of Molecular Sciences 22(3): 1161 (2021)
ResumenPropionic acidemia (PA), one of the most frequent life-threatening organic acidemias, is caused by mutations in either the PCCA or PCCB genes encoding both subunits of the mitochondrial propionyl-CoA carboxylase (PCC) enzyme. Cardiac alterations (hypertrophy, dilated cardiomyopathy, long QT) are one of the major causes of mortality in patients surviving the neonatal period. To overcome limitations of current cellular models of PA, we generated induced pluripotent stem cells (iPSCs) from a PA patient with defects in the PCCA gene, and successfully differentiated them into cardiomyocytes. PCCA iPSC-derived cardiomyocytes exhibited reduced oxygen consumption, an accumulation of residual bodies and lipid droplets, and increased ribosomal biogenesis. Furthermore, we found increased protein levels of HERP, GRP78, GRP75, SIG-1R and MFN2, suggesting endoplasmic reticulum stress and calcium perturbations in these cells. We also analyzed a series of heart-enriched miRNAs previously found deregulated in the heart tissue of a PA murine model and confirmed their altered expression. Our novel results show that PA iPSC-cardiomyocytes represent a promising model for investigating the pathological mechanisms underlying PA cardiomyopathies, also serving as an ex vivo platform for therapeutic evaluation.
Descripción© 2021 by the authors
Versión del editorhttps://doi.org/10.3390/ijms22031161
URIhttp://hdl.handle.net/10261/227955
DOI10.3390/ijms22031161
ISSN1661-6596
E-ISSN1422-0067
Aparece en las colecciones: (CBM) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Cardiomyocytes_Alonso_PV_Art2021.pdf2,71 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

4
checked on 18-abr-2024

SCOPUSTM   
Citations

5
checked on 19-abr-2024

WEB OF SCIENCETM
Citations

6
checked on 28-feb-2024

Page view(s)

112
checked on 21-abr-2024

Download(s)

167
checked on 21-abr-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons